Voting Proxies issued to the Board of Directors


Announcement no. 7/2008                                                         


To the OMX Nordic Exchange Copenhagen                               Copenhagen, 
April 21, 2008                                                                  






Voting Proxies issued to the Board of Directors                                 

In accordance with Section 29 of the Danish Securities Trading Act, cf. Sections
4, no. 8 and 5, subsection 3 of Executive Order No. 1225 of 22 October 2007,    
Curalogic A/S hereby announces that the Board of Directors has received proxies 
from a number of shareholders authorising the Board of Directors of Curalogic   
A/S to vote on their behalf at the Annual General Meeting on April 21, 2008. On 
April 16, 2008 the Board of Directors of Curalogic A/S received voting proxies  
resulting in the Board of Directors being authorised to vote on shares          
corresponding to more than 15 per cent of Curalogic A/S' total aggregate voting 
rights. On April 17, 2008 one of the company's larger shareholders chose to     
withdraw their general voting proxy due to practical considerations and replaced
it with a voting proxy with specific instructions. As a result the Board of     
Directors of Curalogic A/S is hereafter authorised to vote on shares            
corresponding to more than 10 per cent of Curalogic A/S' total aggregate voting 
rights. As of this date the Board of Directors thus controls voting rights which
in aggregate amounts to 13.3 per cent of Curalogic A/S' share capital and voting
rights.                                                                         

On April 21, 2008 after the Annual General Meeting, the authorisation of the    
Board of Directors to vote according to the voting proxies                      
will terminate. Standard notification form according to Executive Order No. 1225
of 22 October 2007 is attached to this announcement.                            


Yours faithfully,                                                               


Curalogic A/S                                                                   


For additional information, please contact:                                     
Peter Moldt, President and CEO, 	Phone +45 99 99 24 01                          
Helle Busck Fensvig, EVP and CFO, 	Phone +45 99 99 24 03                        


About Curalogic                                                                 
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic        
Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash   
resources and has demonstrated its ability to conduct complex clinical studies  
with a small group of development experts. Curalogic has initiated a search     
process to identify development projects offering an attractive risk profile.   
Curalogic expects to conclude an agreement during 2008 that will secure future  
clinical development projects for the Company.                                  



This announcement contains forward-looking statements regarding the Company's   
future financial development and performance and other statements which are not 
historical facts. Such statements are made on the basis of assumptions and      
expectations which, to the best of the Company's knowledge and belief, are      
reasonable, at this time, but may prove to be erroneous in the future.

Attachments

announcement_about_voting_proxies_2.pdf